Cobra Biomanufacturing doubles turnover in second half year
Turnover in the second half of the financial year for UK biopharmaceuticals producer Cobra Biomanufacturing increased by 50% over the preceding six months to 31 March 2005. As a result, Cobra expects to achieve an operating profit for the latest six month trading period and a loss before tax for the financial year 2005 in line with market expectations.
Turnover in the second half of the financial year for UK biopharmaceuticals producer Cobra Biomanufacturing increased by 50% over the preceding six months to 31 March 2005. As a result, Cobra expects to achieve an operating profit for the latest six month trading period and a loss before tax for the financial year 2005 in line with market expectations.
The company, which has facilities in Oxford and Keele, UK and sales offices in Illinois and California, USA, says this performance reflects its focus on the buoyant North American market, which accounted for 86% of turnover in the period.
The results were also helped by a competitive approach to the market for specialist proteins and virus based products and a strong presence in the market for DNA.